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On February 17, 2009 the American Recovery 
and Reinvestment Act (ARRA) – or, as commonly 
referred to in the media, the Stimulus Bill – was 
signed into law. The legislation allocates $787 
billion for federal stimulus spending in an attempt 
to curb the current economic recession. Of the 
total, $150 billion has been allocated to health 
care (Figure 1). Health care represents the largest 
proportion of dedicated funds as well as the 
largest sector of the economy.1 Thus, recovery and 
well-being of the economy is inexorably tied to 
the condition of the healthcare industry. The $150 
billion allotment is viewed as the jumping-off 
point for the Obama administration’s healthcare 
agenda, which seeks to increase access to services 
while controlling cost. Because this will have both 
immediate and long-term effects for everyone in 
the nation, it is imperative for all to understand 
the broad health policy implications. 
Over half (58%) of the health care stimulus  
funds – $87 billion– will be devoted to states 
in the form of matching federal assistance for 
Medicaid.2  The remainder of the health care 
stimulus dollars are pegged for three broad 
initiatives: comparative effectiveness research, 
health information technology, and increased 
funding ($10.4 billion) for the National Institutes 
of Health (NIH).2,3  These three initiatives have the 
potential to profoundly affect healthcare policy 
and the future direction of the healthcare industry. 
Specifically, the ARRA apportions $1.1 billion 
for comparative effectiveness research, one of 
the more controversial funding initiatives.2 
Because comparative effectiveness is in its 
nascent stage in the United States, many have 
presupposed its implications and have a deep-
rooted misunderstanding of this form of science. 
In its simplest form, comparative effectiveness 
research can be boiled down to the comparison of 
alternative treatments for a medical condition to 
determine the best overall treatment strategy. 4  
In practice, it is not this simple; there are many 
methodological and policy challenges. Foremost, 
researchers must determine the appropriate 
outcome measure for which to compare distinct 
or contrasting interventions. Another important 
component of comparative effectiveness research 
is economic evaluations of interventions. However, 
interventions which improve health outcomes 
do not always save money and, in fact, can be 
significantly more expensive than the current 
standard of care. As such, policy makers are forced 
to determine at what costs they are willing to fund 
interventions which improve healthcare. 
While there are clear methodological and 
political challenges to conducting comparative 
effectiveness research, it should not be discounted 
nor touted as the savior of health reform. Rather, 
when implemented as part of an overall evidence-
based medicine agenda, comparative effectiveness 
research has the potential to curb rampant health 
care inflation and improve overall quality of care. 
To oversee funding of comparative effectiveness 
research and to help alleviate the fear of the 
government using findings from this type of 
research to directly dictate medical coverage,  
the Federal Coordinating Council for Comparative 
Effectiveness Research (FCC-CER) was established 
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on March 19, 2009. Comprised of a 15-member 
expert panel, the FCC-CER role is to submit reports 
to Congress on the comparative effectiveness 
research being conducted; it will not be able to 
mandate coverage or set healthcare policy.1,4 
The health care appropriation will also direct 
$19.2 billion to healthcare technology and 
infrastructure investments with the ultimate  
goal of the implementation of an electronic  
health record for every person in the United  
States by 2014.2 To achieve this goal, the funds
will initially be used to provide incentives 
to doctors and hospitals to adopt the use of 
electronic health records.1 
The money will also be used to train workers in 
the use of health information technology and 
improve the security of electronic health records. 
Finally, the legislation allocates an additional 
$10.4 billion to NIH (approximately 1/3 of the 
current NIH budget), which must be spent in  
two years.2,3 Of the total, $2.2 billion is dedicated to 
capital improvements of facilities, infrastructure 
and equipment to improve healthcare 
infrastructure and provide jobs as a way to 
stimulate the economy. The remaining $8.2 billion 
is intended for peer-reviewed research grants.2  
This tidal wave of money devoted to health care 
marks the beginning of a new era in health 
policy, where costs are controlled and quality is 
demanded. Innovation is imperative, and novel 
ideas and approaches to solving the health care 
crisis are welcomed from all disciplines. In order 
to sustain lasting improvement, policy makers 
must remember to continue to invest in the 
nation’s healthcare system after the stimulus 
funds expire.   
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